Strategic partnerships Aspen’s recent collaboration with Lilly to market and distribute GLP-1 Mounjaro in South Africa, plus plans to partner with MSD International, highlight clear opportunities for co-development, licensing, and distributed manufacturing arrangements in high-growth Asia Pacific and African markets.

Sterile manufacturing expansion Significant investments in sterile manufacturing capability in South Africa and planned scale-up for vaccines create sales opportunities for sterile fill-finish services, contract manufacturing, and regulatory-ready supply chain solutions in both regional and global markets.

Emerging markets focus A broad footprint across more than 50 countries with strong presence in APAC and Africa positions Aspen to pursue regional branded and hospital-based portfolios, including post-patent branded medicines and domestic brands that align with public-health needs and payer environments.

Regulatory strength International manufacturing approvals from FDA, TGA, and EDQM suggest a robust quality and compliance framework, enabling faster market access for partner products and opportunities for high-value contract manufacturing and supply agreements with global pharma players.

Revenue resilience While revenue faced fluctuations tied to contract expiries, EBITDA improvements from facility restructuring indicate operational efficiency gains; this points to upsell opportunities in optimized fill-finish capacity, extended line extensions, and higher-margin sterile products for healthcare systems.